GSK’s Jemperli has claimed an edge over its main rival in the endometrial cancer therapy market after showing improved overall survival in a broad patient population in the RUBY trial.

The FDA has cleared GSK's PD-1 inhibitor Jemperli as a treatment for all adult patients with primary advanced or recurrent endometrial cancer, a key part of the company's growth ambitions for the ...

Dostarlimab (Jemperli, GlaxoSmithKline) is indicated 'in combination with platinum-containing chemotherapy for the treatment of adult patients with primary advanced or recurrent endometrial cancer and ...

Dostarlimab (Jemperli) with platinum-based chemotherapy is available on the NHS. It is a possible treatment for when systemic treatment is suitable in adults with primary endometrial cancer that has ...

Genmab has shared the first data on rinatabart sesutecan (Rina-S) in advanced endome | Genmab has shared the first data on ...

As temperatures rose in more than a dozen Middle Eastern and North African countries over the past two decades, cancer ...

A new large analysis led by American Cancer Society (ACS) researchers shows engaging in leisure-time moderate-to-vigorous ...

First-Generation Epidermal Growth Factor Receptor Inhibitors Plus Antiangiogenic Drugs Versus Third-Generation Epidermal Growth Factor Receptor Inhibitors in Advanced Non–Small-Cell Lung Cancer: A ...

the incidence of 14 cancer types increased among people under age ... May 8, 2025 — In the United States, breast, colorectal, endometrial, pancreatic, and kidney cancers are becoming ...

After a blood test during her annual physical uncovered low hemoglobin levels, she underwent numerous tests and learned she had Stage 3 colorectal cancer. “They found a softball- and golf ball ...

uterine (or endometrial), cervical, vulval and vaginal cancer. The RNA binding protein hnRNPL is recruited to chromatin by the PIK3CB promoter-transcribed non-coding RNA and forms phase-separated ...